The use of modern biomarkers for the evaluation of the risk of negative outcomes at chronic heart failure

Nina Mamamtavrishvili, Gulnara Tabidze, Maia Bitskinashvili, Rusudan Abashidze


Chronic heart failure (CHF) is a final link in most diseases of cardiovascular system, and despite the successes in the treatment of CHF, mortality remains high, and the prognosis is disappointing.

Currently, the symptoms and objective signs of HF have been described in detail. However, the specific laboratory tests are limited to a single group of markers - natriuretic peptides. The known limitations for natriuretic peptides and the complexity of CHF pathophysiology condition the topicality of searching for other indicators with the aim to search biological and clinical information. In this regard, the biomarkers involved with other pathophysiological mechanisms of CHF appear to be of interest.

A significant role of a new biomarker, stimulating a growth factor ST2, also known as “mechanical” myocardial stress is considered in this article. The mentioned biomarker has shown a high prognostic potential in the patients with HF. The increase of its soluble form sST2 is associated with the depth of the damage, the severity of disease course and its outcome. The assessment of prognostic value of the biomarker determination, as the predictor of cardio-vascular diseases and their outcomes has been performed.

The topicality of searching for new therapeutic drugs in the combination with “traditional” means of CHF treatment is given in this article.

Based on sST2 concentration in the blood, not only CHF degree and effectiveness of performed therapy can be judged, but also more accurately stratify the risk of progressive complications and, thereby, prevent unfavorable clinical outcome.


chronic heart failure, biomarkers, soluble form of ST2

Full Text:



Buziashvili O.I., Matskeplishvili S.T., Noshina V.I. Chronic heart failure in patients with coronary heart disease: strategic approaches to making optimal clinical decisions. M. NTsSSKh them. A.N. Bakuleva, 2015, 435 p.

Grakova E.V., Kopieva K.V., Teplyakov A.T. et al. Cardiovascular Therapy and Prevention, 2019, 18(4).

Dyleva Yu.A., Gruzdeva O.V., Akbasheva O.E. et al. Clinical laboratory diagnostics, 2017, 62 (10), 599-605.

Isakov L.K., Grakova E.V., Sinkova M.N. and others. Bulletin of Siberian Medicine, 2018, 17(3), 140-50.

Kamardinov D.Kh., Songurov R.N. Noshchina V.I., Buziashvili Yu.I. Journal of Cardiology, 2020, 2, vol. 60, 111-121.

Kopieva K.V., Grakova E.V., Teplyakov A.T. Complex problems of cardiovascular diseases, 2018, 7 (1), 94-101

Mareev V.Yu., Fomin I.V., Ageev F.T. et al. Cardiology, 2018, 58 (65), 8-164.

Skvortsov A.A., Protasov V.N., Narusov O.Yu. et al. Cardiology, 2017, 67(9), 20-33

Skvortsov A.A., Nrusov O.Yu., Muksinova M.D. et al. Cardiology, 2018, 58(129), 27-41.

Bahullyan C.G., Alummoottil G.K., Abdullakutty Y. Indian Heart Journal, 2018, 70 (Suppl. I), S79-84.

Bayes-Genis A., Antonio M., Galan A., Sanz H., Urrustia A. et al. European Journal of Heart Failure, 2012, 14(1), 32-8.

Benjamin E.J., Muntner P., Alonso A. et al. Circulation, 2019, 139 (10), e56-528.

Biasucchi L.M., Bellocci F., Landolina M., Rordorf R. et al. European Heart Journal. 2012, 33 (11), 1344-50.

Boisot S., Beede J., Isakson S. et al. Journal of Cardiac Failure, 2008, 14(9), 732-8.

Bozkurt B. Journal of the American College of Cardiology, 2019, 73(13), 2384-7.

De Filippi C., Daniels L.B., Bayes-Genis A. The Americal Journal of Cardiology, 2015, 115 (7), 59B-63B.

Dieplenger B., Janussi J., Steinmair M. et al. Clinica Chimica Acta, 2009, 409 (1-2), 33-40.

Dinarello C.A. Clinical and exoerimental Rheumatology, 2002, 20/S Supp;/ 27, S1-13, PMID, 14989423.

Fomin I.V. Russian Journal of Cardiology, 2016, 7-13.

Gaggin H.K., Szymonifka j., Bhardsaj al. JACC Jart Failure, 2014, 2 (1), 65-72.

Greene S.J., Butler J., Albert N.M. et al. Journal of the American College of Cardiology, 2018, 72(4), 351-66.

Hartupee J. Journal of Cardiovascular Translational Research, 2013, 6(4), 485-92.

Ibrahim N.E., Januzzi J. Clinical Chemistry, 2017, 63(1), 211-22.

Kakkar R., Lee R.T. Nature Reviews. Drug Discovery, 2008, 7 (10), 827-40.

Ky B., French B., McCloskey K., RameY.E. et al. Circulation, Heart Failure, 2011, 4 (2), 150-7.

Lupon J., Cediel G., Moliner P., Antonio M. et al. Internationaol Journl of Cardiology, 2019, 293, 148-52.

Maisel A., Mueller G., Adams K., Anker S.D. et al. European Journal of heart Failure, 2008, 10 (9), 829-39.

Maggioni Ap. Heart Failure Clinics, 2015, 11(4), 625-35.

Magnusen C., Blomkenberg S. Journal of Iternal Medicine, 2018, 283 (6), 530-43.

Mueller T., Dieplinger B. EJIFCC, 2016, 27 (3), 224-37.

O’Meara E., Prescott M.F., Clagett B. et al. Circulation^ Heart Failure, 2018, 11(5), e004446.

Ponikowski P., Voors A.A., Anker S.D. et al. European Heart Journal, 2016, 37 (27), 2129-200.

Pascual-Figal D.A., Ordonez-Lianis J., Tornell P.L. et al. Journal of American College of Cardiology, 2009, 54 (23), 2174-79.

Sanada S., Hakuno D., Higgins L.J. et al. Journal of Clinical Investigation, 2007, 117 (6), 1538-49.

Schmitz J., Owyang A., Oldham E. et al. Immunity, 2005, 23 95), 479-90.

Seki K., Sanada S., Kudiniva A.Y., Steinhauser M.L., Handa V. et al. Circulation, Heart Failure, 2009, 2(6), 684-91.

Skali H., Gerwien R., Meyer T.E. et al. Journal of Cardiovasculat Translational Research, 2016, 9(5-6), 421-8.

Tominaga S. FEBS Letters, 1989, 258 (2), 301-304.

Weinberg B.O., Shimpo M., De Keulenaer G.W. et al. Circulation, 2002, 106 (23), 2961-66.

Yancy G.W., Jessup M., Bozkurt B. et al. Journal of American College of Cardiology, 2013, 62 (16), 2147-239.

Yancy G.W., Jessup M., Bozkurt B., Butler J. et al. Circulation, 2017, 136 (6), e137-61.

Yucel O., Gul I. Zararsiz A., Demirpence O. et al. Herz, 2018, 43 (5), 455-60.

Zile M.R., O’Meara E., Clagett B. et al. Journal of the American College of Cardiology, 2019, 73(7), 795-806.


  • There are currently no refbacks.


Become a REVIEWER 


ISSN: 2346-8491 (online)